AstraZeneca NYSE:AZN, a global pharmaceutical company focused on medicines including cancer and rare-disease treatments, maintained its 2026 and 2030 forecasts after second-quarter core earnings exceeded market expectations, helping ease some investor concern following recent clinical-trial setbacks. Core earnings reached $2.63 per share, compared with a company-compiled consensus estimate of $2.48. Quarterly revenue increased 5% to $15.38 billion, broadly matching the $15.39 billion consensus estimate. AstraZeneca shares rose 1.7% during morning trading following the results, although the stock remained approximately 7% lower for the year. Chief Executive Pascal Soriot said the company continued to believe it had the scientific capabilities, development pipeline and personnel required to meet its long-term ambitions.
AstraZeneca is targeting annual revenue of $80 billion by 2030, which JPMorgan analysts said remained achievable after the earnings beat and in-line sales. Demand for oncology and rare-disease medicines continued to support growth, with sales from the two areas increasing 15% and 8%, respectively. China, AstraZeneca's second-largest market, was a weaker area as revenue declined 13% because of generic competition and policy changes. The company maintained its expectation that 2026 core earnings per share would increase by a low-double-digit percentage at constant exchange rates, while revenue is expected to grow at a mid-to-high-single-digit rate. AstraZeneca also raised the estimated peak-sales potential of experimental respiratory medicine tozorakimab from $3 billion to more than $5 billion.
Clinical execution remains an important part of the investment case following setbacks involving nerve-disease treatment Wainua and experimental breast-cancer therapy camizestrant. AstraZeneca began six Phase III trials during the second quarter for elecoglipron, an oral GLP-1 candidate being studied in obesity and type 2 diabetes, making it one of the company's largest late-stage development programs. Investors are also awaiting results from two late-stage cancer studies as AstraZeneca prepares to report more than 20 Phase III readouts over the following 18 months. Finance chief Aradhana Sarin said supply and distribution costs had increased because of the Iran war, although she did not quantify the impact. The earnings beat and unchanged guidance may support confidence in AstraZeneca's near-term performance, while upcoming oncology results, elecoglipron development, lower Chinese revenue and higher logistics expenses could remain significant factors in evaluating progress toward the $80 billion target.